Dynamic immunoediting by macrophages in homologous recombination deficiency-stratified pancreatic ductal adenocarcinoma
Drug Resistance Updates · 2024-09 · 76 · 101115
DOI: 10.1016/j.drup.2024.101115 ↗Kurz gefasst
Fachartikel in der Zeitschrift Drug Resistance Updates, 2024-09. Verfasst von Wei-Feng Hong und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pancreas Center, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou…. Hauptthemen laut MEDLINE: Carcinoma, Pancreatic Ductal, Homologous Recombination, Macrophages, Pancreatic Neoplasms. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 91 Literaturangaben.
Abstract (Originalsprache)
Pancreatic ductal adenocarcinoma (PDAC) is a lethal disease, notably resistant to existing therapies. Current research indicates that PDAC patients deficient in homologous recombination (HR) benefit from platinum-based treatments and poly-ADP-ribose polymerase inhibitors (PARPi). However, the effectiveness of PARPi in HR-deficient (HRD) PDAC is suboptimal, and significant challenges remain in fully understanding the distinct characteristics and implications of HRD-associated PDAC. We analyzed 16 PDAC patient-derived tissues, categorized by their homologous recombination deficiency (HRD) scores, and performed high-plex immunofluorescence analysis to define 20 cell phenotypes, thereby generating an in-situ PDAC tumor-immune landscape. Spatial phenotypic-transcriptomic profiling guided by regions-of-interest (ROIs) identified a crucial regulatory mechanism through localized tumor-adjacent macrophages, potentially in an HRD-dependent manner. Cellular neighborhood (CN) analysis further demonstrated the existence of macrophage-associated high-ordered cellular functional units in spatial contexts. Using our multi-omics spatial profiling strategy, we uncovered a dynamic macrophage-mediated regulatory axis linking HRD status with SIGLEC10 and CD52. These findings demonstrate the potential of targeting CD52 in combination with PARPi as a therapeutic intervention for PDAC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pancreas Center, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, Guangdong, China; Department of Radiation Oncology, Zhejiang Cancer…
- Department of Pancreas Center, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, Guangdong, China.
- Cosmos Wisdom Biotech, co. ltd, Building 10, No. 617 Jiner Road, Hangzhou, Zhejiang, China.
- Department of Urology, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, Guangdong, China.
- Mills Institute for Personalized Cancer Care, Fynn Biotechnologies Ltd. Jinan, Shandong, China.
- Division of Oncological Sciences, Knight Cancer Institute, Oregon Health & Science University, Portland, USA.
Zitieren
APA
Hong, W. F., Zhang, F., Wang, N., Bi, J. M., Zhang, D. W., Wei, L. S., Song, Z. T., Mills, G. B., Chen, M. M., Li, X. X., Du, S. S., & Yu, M. (2024). Dynamic immunoediting by macrophages in homologous recombination deficiency-stratified pancreatic ductal adenocarcinoma. Drug Resistance Updates, 76, 101115. https://doi.org/10.1016/j.drup.2024.101115
Vancouver
Hong WF, Zhang F, Wang N, Bi JM, Zhang DW, Wei LS, et al. Dynamic immunoediting by macrophages in homologous recombination deficiency-stratified pancreatic ductal adenocarcinoma. Drug Resistance Updates. 2024;76:101115. doi:10.1016/j.drup.2024.101115
BibTeX
@article{Hong2024,
author = {Hong, Wei-Feng and Zhang, Feng and Wang, Nan and Bi, Jun-Ming and Zhang, Ding-Wen and Wei, Lu-Sheng and Song, Zhen-Tao and Mills, Gordon B and Chen, Min-Min and Li, Xue-Xin and Du, Shi-Suo and Yu, Min},
title = {Dynamic immunoediting by macrophages in homologous recombination deficiency-stratified pancreatic ductal adenocarcinoma},
journal = {Drug Resistance Updates},
year = {2024},
volume = {76},
pages = {101115},
doi = {10.1016/j.drup.2024.101115}
}
EUVIMED